Manufacturers should not wait for final HTA scopes to test whether their evidence package can addres...
Read morePricing research is often treated as a launch-stage exercise focused on testing a target price. But ...
Read moreDifferent budget pressures create different payer pricing challenges Healthcare budget pressur...
Read morePricing strategies rarely fail because of one decision. More often, price potential is gradually ero...
Read morePrice ambition is only defensible when the evidence can carry it Manufacturers can no longer r...
Read morePricing strategy is often treated as a launch activity. However, by the time teams begin detailed pr...
Read moreAt the start of 2026, we identified five key pharmaceutical pricing and market access trends expecte...
Read moreEarly HTA scientific advice reduces price and reimbursement risk by informing ev...
Read moreWhile missing an EU Joint Scientific Consultation (JSC) is suboptimal, the greater strategic concern...
Read moreFrom 1 April 2026, AIFA’s updated HTA guidelines will come into effect, making ...
Read more